Page 72 - ITPS-7-2

INNOSC Theranostics and
Pharmacological Sciences Youth brain health check and dysregulation

doi: 10.2105/AJPH.2015.302843 risk score (GARS) , a predictor of vulnerability to opioid
™
dependence. Front Biosci (Elite Ed). 2018;10(1):175-196.
8. Thorpe HHA, Hamidullah S, Jenkins BW, Khokhar JY.
Adolescent neurodevelopment and substance use: Receptor doi: 10.2741/e816
expression and behavioral consequences. Pharmacol Ther. 20. Gold MS, Blum K, Febo M, et al. Molecular role of dopamine
2020;206:107431.
in anhedonia linked to reward deficiency syndrome (RDS) and
doi: 10.1016/j.pharmthera.2019.107431 anti- reward systems. Front Biosci (Schol Ed). 2018;10(2):309-325.
9. Strulik H. Opioid epidemics. Econ Hum Biol. 2020;37:100835. doi: 10.2741/s518
doi: 10.1016/j.ehb.2019.100835 21. Blum K, Modestino EJ, Gondre-Lewis M, et al. The
benefits of genetic addiction risk score (GARS ) testing
™
10. Horseman C, Meyer A. Neurobiology of addiction. Clin
Obstet Gynecol. 2019;62(1):118-127. in substance use disorder (SUD). Int J Genom Data Min.
2018;2018(1):115.
doi: 10.1097/GRF.0000000000000416
doi: 10.29014/IJGD-115.000015
11. Blum K, Modestino EJ, Badgaiyan RD, et al. Analysis of
evidence for the combination of pro-dopamine regulator 22. Blum K, Thanos PK, Wang GJ, et al. The food and drug
(KB220PAM) and naltrexone to prevent opioid use disorder addiction epidemic: Targeting dopamine homeostasis. Curr
relapse. EC Psychol Psychiatr. 2018;7(8):564-579. Pharm Des. 2018;23(39):6050-6061.
doi: 10.2174/1381612823666170823101713
12. Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY.
Injectable naltrexone, oral naltrexone, and buprenorphine 23. Blum K, Badgaiyan RD, Braverman ER, et al. Hypothesizing
utilization and discontinuation among individuals treated that, A pro-dopamine regulator (KB220Z) should optimize, but
for opioid use disorder in a United States commercially not hyper-activate the activity of trace amine-associated receptor
insured population. J Subst Abuse Treat. 2018;85:90-96. 1 (TAAR-1) and induce anti-craving of psychostimulants in the
long-term. J Reward Defic Syndr Addict Sci. 2016;2(1):14-21.
doi: 10.1016/j.jsat.2017.07.001
doi: 10.17756/jrdsas.2016-023
13. Daoust M, Legrand E, Gewiss M, et al. Acamprosate modulates
synaptosomal GABA transmission in chronically alcoholised 24. Blum K, Modestino EJ, Neary J, et al. Promoting precision
rats. Pharmacol Biochem Behav. 1992;41(4):669-674. addiction management (PAM) to combat the global opioid
crisis. Biomed J Sci Tech Res. 2018;2(2):1-4.
doi: 10.1016/0091-3057(92)90210-7
doi: 10.26717/BJSTR.2018.02.000738
14. Blum K, Baron D, Lott L, et al. In search of reward deficiency
syndrome (RDS)-free controls: The “Holy Grail” in genetic 25. Blum K, Gondré-Lewis MC, Baron D, et al. Introducing
addiction risk testing. Curr Psychopharmacol. 2020;9(1):7-21. precision addiction management of reward deficiency
syndrome, the construct that underpins all addictive
15. Baron D, Blum K, Chen A, Gold M, Badgaiyan RD.
Conceptualizing addiction from an osteopathic behaviors. Front Psychiatry. 2018;9:548.
perspective: Dopamine homeostasis. J Am Osteopath Assoc. doi: 10.3389/fpsyt.2018.00548
2018;118(2):115-118.
26. Volkow ND. Toward individualized treatment for substance
doi: 10.7556/jaoa.2018.026 abuse. Addict Sci Clin Pract. 2010;5(2):2.
16. Blum K, Modestino EJ, Gondré-Lewis M, et al. “Dopamine 27. Blum K, Baron D, McLaughlin T, Gold MS. Molecular
homeostasis” requires balanced polypharmacy: Issue with neurological correlates of endorphinergic/dopaminergic
destructive, powerful dopamine agents to combat America’s drug mechanisms in reward circuitry linked to endorphinergic
epidemic. J Syst Integr Neurosci. 2017;3(6). deficiency syndrome (EDS). J Neurol Sci. 2020;411:116733.
doi: 10.15761/JSIN.1000183 doi: 10.1016/j.jns.2020.116733
17. Kenneth B, Edward MJ, Marjorie GLC, et al. Pro-dopamine 28. Rosen GD, Chesler EJ, Manly KF, Williams RW. An
regulator (KB220) a fifty year sojourn to combat reward informatics approach to systems neurogenetics. Methods
deficiency syndrome (RDS): Evidence based Bibliography Mol Biol. 2007;401:287-303.
(Annotated). CPQ Neurol Psychol. 2018;1:2.
doi: 10.1007/978-1-59745-520-6_16
18. Febo M, Blum K, Badgaiyan RD, et al. Enhanced functional 29. Blum K, Febo M, Smith DE, et al. Neurogenetic and
connectivity and volume between cognitive and reward epigenetic correlates of adolescent predisposition to and
centers of naïve rodent brain produced by pro-dopaminergic risk for addictive behaviors as a function of prefrontal
agent KB220Z. PLoS One. 2017;12(4):e0174774.
cortex dysregulation. J Child Adolesc Psychopharmacol.
doi: 10.1371/journal.pone.0174774 2015;25(4):286-292.
19. Blum K, Chen ALC, Thanos PK, et al. Genetic addiction doi: 10.1089/cap.2014.0146

Volume 7 Issue 2 (2024) 12 doi: 10.36922/itps.1472